Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.

The global photodynamic therapy (PDT ... bladder cancer, and actinic keratosis. The therapy uses photosensitisers to make tissues light-sensitive, allowing targeted destruction of abnormal ...

Actinic keratoses are common in older individuals and topical immunotherapy is an important treatment when multiple lesions are present. To assess the efficacy of 5-fluorouracil in treating ...

Immunotherapy. 2012;4(9):939-945. The percentage of patients achieving complete clearance of their AKs in the 5-FU group was 19, 28.2 and 52.6% in the 1-, 2- and 4-week treatment groups, respectively.

The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

The RhodoLED XL is approved by the FDA in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

US-based company Biofrontera has announced topline results from a Phase III trial evaluating its drug-device therapy, Ameluz ...

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a ...